Get the Stockscreener App
5.06
2.32%
-0.12
Protara Therapeutics Inc stock is traded at $5.06, with a volume of 313.48K.
It is down -2.32% in the last 24 hours and up +2.02% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$5.18
Open:
$5.31
24h Volume:
313.48K
Relative Volume:
0.77
Market Cap:
$195.22M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.7943
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
-1.17%
1M Performance:
+2.02%
6M Performance:
+41.34%
1Y Performance:
+104.86%
1-Day Range:
$4.91
$5.34
1-Week Range:
$4.91
$5.39
52-Week Range:
$2.21
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.06 | 199.85M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.69 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.80 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.61 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.11 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Why Protara Therapeutics Inc. (1KPA) stock is listed among top recommendationsMarket Movement Recap & Safe Entry Momentum Tips - newser.com
Will Protara Therapeutics Inc. stock benefit from upcoming earnings reports2025 Retail Activity & Safe Investment Capital Preservation Plans - newser.com
Chart based analysis of Protara Therapeutics Inc. trendsJuly 2025 Big Picture & Reliable Entry Point Trade Alerts - newser.com
Will Protara Therapeutics Inc. stock attract more institutional investors2025 Trading Volume Trends & Daily Growth Stock Investment Tips - newser.com
Why Protara Therapeutics Inc. stock appeals to analystsWeekly Risk Report & Risk Controlled Daily Plans - newser.com
Can Protara Therapeutics Inc. (1KPA) stock attract analyst upgradesMarket Sentiment Summary & Daily Profit Focused Stock Screening - newser.com
Visualizing Protara Therapeutics Inc. stock with heatmapsEarnings Risk Summary & Reliable Price Breakout Signals - newser.com
How Protara Therapeutics Inc. (1KPA) stock reacts to fiscal policiesBuy Signal & Community Verified Trade Alerts - newser.com
What recovery options are there for Protara Therapeutics Inc.Oil Prices & Smart Swing Trading Alerts - newser.com
Is Protara Therapeutics Inc. stock a safe haven assetVolume Spike & Daily Volume Surge Signals - newser.com
Can technical indicators confirm Protara Therapeutics Inc.’s reversalTrade Analysis Report & Daily Risk Controlled Trade Plans - newser.com
Risk adjusted return profile for Protara Therapeutics Inc. analyzedJuly 2025 Recap & Safe Investment Capital Preservation Plans - newser.com
What is the fair value estimate for Protara Therapeutics Inc. (1KPA) stock in 20252025 Sector Review & Proven Capital Preservation Methods - newser.com
Will Protara Therapeutics Inc. stock rally after Fed decisionsJuly 2025 PreEarnings & Capital Efficient Trade Techniques - newser.com
What analysts say about Protara Therapeutics Inc stockGlobal Trade Effects & Small Entry Investment Ideas - earlytimes.in
Is NINtec Systems Limited Stock Poised for a Breakout in YEARSupport and Resistance Levels & Affordable Growth Trading - earlytimes.in
Protara Therapeutics (NASDAQ:TARA) Trading Down 1.2%Here's What Happened - MarketBeat
Long term hold vs stop loss in Protara Therapeutics Inc.July 2025 Reactions & Daily Profit Focused Screening - newser.com
How Protara Therapeutics Inc. stock trades during market volatilityWeekly Profit Analysis & AI Forecasted Stock Moves - newser.com
How to read the order book for Protara Therapeutics Inc.July 2025 Update & Safe Entry Point Alerts - newser.com
Will Protara Therapeutics Inc. price bounce be sustainable2025 Market WrapUp & High Accuracy Swing Entry Alerts - newser.com
Measuring Protara Therapeutics Inc.’s beta against major indicesQuarterly Growth Report & Capital Efficient Trading Techniques - newser.com
Real time pattern detection on Protara Therapeutics Inc. stockWatch List & Long Hold Capital Preservation Plans - newser.com
Is Protara Therapeutics Inc. (1KPA) stock inflation resilient2025 Volatility Report & AI Powered Trade Plan Recommendations - newser.com
Protara Therapeutics’ Choline Chloride Study: A Potential Game-Changer for Intestinal Failure Treatment - MSN
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):